

BIOTECH MEDICS, INC.
A Nevada Corporation

December 31, 2011

Supplemental Information

**Rule 15c2-11 of the Securities and
Exchange Act of 1934, as Amended**

Solely for OTC Markets

OTC MARKETWIRE DISCLOSURE STATEMENT

SUPPLEMENTAL INFORMATION PURSUANT TO RULE 15c2-11

OF THE SECURITIES AND EXCHANGE ACT OF 1934

Current Information Regarding

BIOTECH MEDICS, INC.

The following information is provided to assist securities brokerage firms with “due diligence” compliance. This statement has not been filed with the FINRA or any other regulatory agency. This information is set forth below as to BIOTECH MEDICS, INC. (referred to as “We” or the “Company”). We were incorporated on December 29, 1997, in the State of Nevada, as Summit Property Group, Inc. (hereinafter referred to as “the Issuer”). This information is provided for the purpose of providing information to broker-dealers trading in the securities of the Issuer in compliance with Rule 15c211(a)(5) of the Securities Exchange Act of 1934, as amended. The information provided follows the same numbering system found in the rule to wit:

Item 1. Exact Name of Issuer and Predecessor:

Issuer:

BioTech Medics, Inc. from November 19, 2004 to present

Previous Names:

Corbel Holdings, Inc. from April 30, 2001 to November 18, 2004

Summit Property Group, Inc. from December 29, 1997 to April 29, 2001

Item 2. Address of Issuer’s Principal Executive Offices:

Corporate Services of Nevada
507 North Division Street
Carson City, NV 89703
Telephone No.: (972) 274-5533
Facsimile No.: (972) 692-5441

The Company Website Address: www.biotechmedics.com

Item 3. State and Date of Incorporation:

We were incorporated on December 29, 1997, in the State of Nevada.

Item 4. Exact Title and Class of Security:

We are currently authorized to issue two classes of stock, common stock and preferred stock.

The CUSIP for our common stock Symbol: BMCS is **090699307**.

Our common stock has only been quoted on the Pink Sheets on an unsolicited basis since it initiated trading on the Pink Sheets. Our current stock symbol is "BMCS." Pink Sheets had discontinued the posting of information on pinksheets.com for a while due to the fact the Company posted the pre-requisite information on the Company web site.

Our preferred stock does not have a CUSIP and is not publicly traded.

Item 5. Par Value or Stated Value of Security:

Our common stock has a par value of \$0.001 per share.

Preferred Stock par value of \$.001 per share.

Item 6. Number of Shares or Total Amount of the Securities Outstanding As of the End of the Issuer's Most Recent Fiscal Quarter and Fiscal Year and any Offerings of Securities in the Last Two Years:

A. Number of Shares Outstanding
Common Stock

We are authorized to issue 500,000,000 shares of common stock, par value \$0.001.

As of December 31, 2011, we provided information in response to this item, we had 157,206,178 shares of common stock issued and outstanding, held by approximately 300 legal shareholders. There are an additional 4,473 former Corbel Holdings shareholders who own one (1) share of Corbel stock which is subject to a U.S. Fed. Tampa Dist Judge Permanent Injunction as having been illegally issued as dividends or distributed by either Jeffrey G. Turino and/or John M. Edwards in 2003 & 2004.

According to the transfer agent of the 157,206,178 shares of common stock, 107,759,125 are restricted and 49,447,053 were free trading. We estimate that 20 million shares are in the float.

All shares are equal to each other with respect to liquidation and dividend rights. Holders of voting shares are entitled to one vote for each share that they own at any shareholders' meeting. Holders of our shares of common stock do not have cumulative voting rights.

Each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. The holders are not permitted to vote their shares cumulatively. Accordingly, the shareholders of our common stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of our directors and, in such event, the holders of the remaining minority shares will not be able to elect any of the such directors. The vote of the holders of a majority of the issued and outstanding shares of common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law.

Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.

Preferred Stock

As of the date we provided information in response to this item, no shares of our preferred stock have been issued.

Preferred stock may be issued in series with preferences and designations as the Board of Directors may from time to time determine. The board may, without shareholders approval, issue preferred stock with voting, dividend, liquidation and conversion rights that could dilute the voting strength of our common shareholders and may assist management in impeding an unfriendly takeover or attempted changes in control. There are no restrictions on our ability to repurchase or reclaim our preferred shares while there is any arrearage in the payment of dividends on our preferred stock.

B. Offerings of Securities

Within the last two year periods ending on the date of our last fiscal year and as of the date of this Disclosure Statement, we have had the following offerings of our securities:

The Company has not had any 504 Reg D offerings of stock since 2007.

Item 7. Name and Address of Transfer Agent:

Transfer Online
512 SE Salmon Street
Portland OR 97214
Telephone No. (503) 227-2950

On the web at : www.transferonline.com

Our transfer agent is registered under the Exchange Act.

Item 8. Nature of the Issuer's Business:

A. Business Development

We were organized on December 29, 1997, to operate as a property owner and/or management service. On December 7, 2004, we acquired HaloLaser BioTherapy, LLC via a reverse merger, and now focus on alternative medicine, Nutraceuticals, alcohol free hand sanitizer and high powered deep penetrating laser medical devices for the twenty-first century.

Information concerning the following specific items is furnished to provide a more complete understanding of the issuer's business development:

1. The form of organization of the Issuer;

We are a Nevada public corporation.

2. The year that the Issuer (or any predecessor) was organized;

We were incorporated on December 29, 1997, in the State of Nevada, as Summit Property Group, Inc.

3. The Issuer's fiscal year end date;

Our fiscal year end date is December 31.

4. Whether the Issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding;

We have not been in bankruptcy, receivership or any similar proceeding.

5. Whether the Issuer has made any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets in the ordinary course of business.

On December 7, 2004, we acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock.

In March, 2005, we acquired substantially all of the assets of FHJ Scientific, Inc., in exchange for 1,250,000 shares of our common stock, restricted in accordance with Rule 144 and signed a promissory note. Due to two reverse stock splits in 2007, the Company issued additional shares to FHJ and FHJ now holds 3,019,875 common shares.

In July, 2007, we acquired the assets of BioBody Balance nutraceutical beverage for 5,000,000 common restricted 144 shares.

Both Keith Houser, as Chairman/CEO and Charles R. Crane as President and director of the Company have had **Executive Employment Agreements** since December 7, 2004. The Company has been unable to compensate Mr. Houser and Dr. Crane pursuant to the Agreements. Both Dr. Crane and Mr. Houser have permitted a portion of their compensation to be capitalized as research and development costs toward the development of products and services offered by the Company. The balance sheet of the Company reflects a portion of these sums as amortized intangible assets.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;

None that have not been extended, paid off or re-negotiated.

7. Any change of control;

On December 7, 2004, we acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock. The entire prior board of directors resigned and the Company came under new management and a new board of directors. The Company will notify the proper authorities should there be a change in control.

8. Any increase in 10% or more of the same class of outstanding equity securities;

On December 7, 2004, the Company acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock. At the time this did not constitute an increase greater than 10% of outstanding equity securities. Through the issuance of 504 stock in 2005 and 2006 to raise operating capital and the issuance of 144 shares in 2007 to acquire assets, as well as to raise operating capital in 2011 this did constitute a greater than 10% increase or more of the same class of outstanding equity securities. The details are specified in ¶ 5 above.

9. Describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization;

In June, 2007 the board of directors filed with the various regulatory authorities and had approved a ten for one (10 to 1) reverse stock split.

In November, 2007 the board of directors filed with the various regulatory authorities and had approved a twenty for one (20 to 1) reverse stock split.

The two reverse stock splits were to limit the ability of several persons who have subsequently been criminally indicted and two persons in civil SEC Enforcement Court Actions pleading guilty to illegal manipulation of the Company stock and/or having issued shares that were not registered and/or exempt from registration and placing those shares illegally into the retail market. Over 50 million shares were illegally placed into the market. The two reverse stock splits reduced those shares to 250,000.

10. Any delisting of the Issuer's securities by any securities exchange or NASDAQ or deletion from the OTC Bulletin Board;

Our securities have **not** been de-listed by any securities exchange or NASDAQ or deleted from the OTC Bulletin Board.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the Issuer that could have a material effect on the Issuer's business, financial condition, or operations. Any current, past or pending trading suspensions by a securities regulator.

On July 1, 2011, the Issuer won a \$1.78 Million FINRA AWARD against the dissolved NevWest Securities, LLC, of Las Vegas, Nevada. FINRA had already terminated NevWest from operations and the SEC had commenced a civil action against two of the former officers of NevWest. In October, 2011, the Company commenced a civil action against NevWest in a Las Vegas, Nevada District Court which did affirm the FINRA AWARD.

The Company has made a claim before the insurance carrier which Bonded NevWest during the period in which the Company claim covered the FINRA AWARD.

The former Chairman SERGEY RUMYANTSEV of NevWest signed in 2011 an Agreed Order with the SEC to pay a fine and cooperate in any agency awards. To date SERGEY RUMYANTSEV has not cooperated with the Company in regard to our FINRA AWARD.

Twice within the past two (2) years the Company bank checking account and VISA card were hacked into resulting in over \$46,000 in fraudulent checks and/or credit card charges. The Company working with local police, FINCEN, the FBI and banking authorities were able to stop the criminal theft and fraud and there was no financial loss to the Company with the exception of having to re-order new checks and a new credit card with new account numbers.

B. Business of Issuer

We (1) sell one or more types of FDA 510(k) cleared high powered deep penetrating medical laser devices for the treatment of numerous symptoms and physical ailments of the human body associated with pain; (2) train and certify medical professionals in the use of our laser devices; (3) manage; market and affiliate with BioTech Laser pain management and wellness medical centers in the United States; and (4) acquired US letters of patent and proprietary SHBAN persistent antiseptic products; and (5) we sell BioBody Balance nutritional products and/or devices that compliment our goals of offering alternative medicine for the twenty-first century.

Information concerning the following specific items is provided to the extent material to an understanding of the issuer:

1. Issuer's primary and secondary SIC Codes;

Primary: 8090 (Health & Allied Services)

Secondary: 62134 (Physical, Occupational Therapy)

Other: 62111 (Offices of Physician)

62151 (Medical & Diagnostic Labs)

2. If the Issuer has never conducted operations, is in the development stage or is currently conducting operations;

We are currently conducting operations, but our operations require additional capital as if in the development stage. The Company is dependant upon raising additional capital and/or selling products to remain an ongoing concern. Failure by the Company to do so would have significantly adverse consequences including the possibility of the Company having to cease operations.

Our lack of a profitable operating history makes it difficult for us to evaluate our future business prospects and make decisions in implementing our business plan. Investors are unable to determine whether we will ever become profitable, which increases their investment risk.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

- our profitability;
- our ability to secure contracts;
- the effectiveness of our remediation processes; and
- the amount of our capital expenditures, including real estate development projects.

We cannot assure investors that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing

shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences, and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

3. State the names of any parent, subsidiary, or affiliate of the issuer, and describe its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure document;

The Company issues a combined financial statement with the income and expenses of BioTech Laser Centers of Texas, LLC, Dallas, Texas.

4. Effect of existing or probable governmental regulations on the business;

The recent passing of the Congressional legislation known as “Obamacare” officially called the *Patient Protection and Affordable Care Act* may have an extreme adverse effect on all medical practices. The legislation and whether it is constitutional will be heard by the U.S. Supreme Court in July, 2012 and the outcome is tenuous.

We are directly affected by economic and political conditions, broad trends in business, bank finance and changes in the general economic conditions of the country and the world.

Buying customs in the industry, the majority of wholesale sales are subject to a written agreement. Retail Internet sales are on a case via check and/or credit card basis. As a result, they could be changed or eliminated at any time. If these payments were to be reduced or eliminated for competitive or other reasons, our business could be materially adversely affected.

We may fail to attract customers in a cost-effective manner and our profitability and growth may be impaired.

Our profitability and growth will depend on establishing a customer base in a cost-effective manner.

Although we plan to spend financial resources on advertising and related expenses, there are no assurances that these efforts will succeed in attracting customers. The financial resources that we allocate to attracting customers may be inadequate. In addition, we believe that rates for desirable advertising and marketing placements are likely to increase in the foreseeable future, and we may be disadvantaged relative to our ability to expand or maintain our advertising and marketing commitments.

Additionally, filter software programs that limit or prevent our advertisements and other communications from being displayed on or delivered to our current and potential customers' computers are becoming increasingly available. If this type of software becomes widely accepted, it would negatively affect Internet advertising.

Finally, our sales and marketing methods are subject to regulation by the Federal Trade Commission (FTC), the US Food & Drug Administration (FDA), the various state Attorneys General and Consumer Protection regulations. The rules and regulations of the FTC, FDA,

impose specific limitations on our sales methods, including our advertising. If we do not achieve our advertising objectives, our profitability and growth may be impaired.

The Company, its officers and/or directors make no warranties and/or representations whatsoever regarding the Company stock certificates and their being accepted by any broker dealer. FINRA and the broker dealers have made it almost impossible for a penny stock below ten cents and in some cases below a dollar to be deposited into their accounts. The broker dealers allege due to the speculative nature of the stock it is too risky to be considered by the broker dealer. These are specious claims considering the fact the broker dealers permit highly speculative options and futures trading, margin accounts and shorting of stocks.

There has also been periods of “fails to deliver” as reported by the SEC within the past two years. The values of total fails-to-deliver shares represent the aggregate net balance of shares that failed to be delivered as of a particular settlement date. If the aggregate net balance of shares that failed to be delivered is less than 10,000 as of a particular settlement date prior to September 16, 2008, then no record will be present in the file for that date even if there are fails in that security. If the aggregate net balance of shares that failed to be delivered is zero as of a particular settlement date on or after September 16, 2008, then no record will be present in the file for that date. Fails to deliver on a given day are a cumulative number of all fails outstanding until that day, plus new fails that occur that day, less fails that settle that day. The figure is not a daily amount of fails, but a combined figure that includes both new fails on the reporting day as well as existing fails. In other words, these numbers reflect aggregate fails as of a specific point in time, and may have little or no relationship to yesterday's aggregate fails. Thus, it is important to note that the age of fails cannot be determined by looking at these numbers. In addition, the underlying source(s) of the fails-to-deliver shares is not necessarily the same as the underlying source(s) of the fails-to-deliver shares reported the day prior or the day after.

An investor can check on the broker dealer and/or DTCC fails to deliver by going on the internet to <http://www.sec.gov/foia/docs/failsdata.htm>. Or to look at fails to deliver charts on the internet go to: <http://failstodeliver.com/> type in BMCS.

Governmental regulation of small business, under which this Company qualifies is extremely onerous and detrimental to the viability of the Company. Regulations placed upon the Company by governmental regulators rarely provide the security and transparency sought by the regulators. Take for instance Lehman Brothers. They were a fully reporting, audited entity yet they failed causing devastating losses to investors. In 2009, nearly 140 audited banks failed in the USA, and over 170 audited banks failed in 2010. Let's not forget Solyndra Solar failing in 2011, a fully reporting NASDAQ company.

It would be better if the SEC just created a High Risk Gamble Stock category. Reduce and or eliminate most of the filing and compliance issues and just represent that the stock purchase is equal to that of a wager in gambling. You have a very slim chance of winning, and your investment is totally at risk, just as it would be in betting or gaming.

The Company stock is shorted on a regular basis. So long as the SEC permits shorting of penny stocks, they will be volatile.

This Company stock is highly speculative and these securities involve a high degree of risk and should be considered only by persons who can afford the loss of their entire investment.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this document. Any representation to the contrary is a criminal offense.

5. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

\$50,000 in Research & Development has been allocated over the last two fiscal years. The cost will be amortized over 5 years. The cost will be repaid over time from both wholesale and retail sales.

6. Costs and effects of compliance with environmental laws (federal, state and local);

The Company is required to comply with the Food & Drug Administration in the operation of medical lasers. The cost of compliance is less than \$2,500 per year per laser. The medical lasers are declared “non-hazardous” by the FDA.

Our sales and marketing methods are subject to regulation by the Federal Trade Commission (FTC), the US Food & Drug Administration (FDA), the various state Attorneys General and Consumer Protection regulations. The rules and regulations of the FTC, FDA, impose specific limitations on our sales methods, including our advertising. If we do not achieve our advertising objectives, our profitability and growth may be impaired.

Since April 17, 2009 the Environmental Protection Agency (EPA) has declared that human breathing (more specifically humans exhaling carbon dioxide) or that exhaling is a hazard to the world this could place an extreme cost and effect upon the Company.

Source: <http://www.thenewamerican.com/tech-mainmenu-30/environment/1022>

7. Number of total employees and number of full time employees.

We have a total of 3 employees, all 3 are officers of the Company. We have only one (1) full time employee.

C. Investment Policies

Not Applicable. The Company does not have any current third party investments.

Item 9. Nature of Products and Services Offered:

1. Principal products or services, and their markets;

The Company has developed BioTech L3aser Protocols for use in FDA 510(k) authorized medical lasers. We use two (2) of the most powerful Class III B and Class IV medical lasers in the United States. The BioTech L3aser's proprietary protocols, frequency spectrum and high wattage provide the capabilities necessary to work the laser's healing effect to reduce or eliminate muscle, bone, nerve, and/or arthritic pain through biological stimulation over any area of the body (except the eyes).

The BioTech Pain Management & Wellness Centers as affiliated centers operate in four (4) states (California, New Mexico, Texas and Florida) in five (5) clinics. These centers combine the proprietary BioTech L3aser medical laser protocols, with nutrition education, use of SHBAN persistent antiseptic sanitizers together with BioBody Products and lifestyle change programs to provide immediate aid to those in acute and chronic pain and help patients regain strength and well-being.

2. Distribution methods of the products or services;

The high powered deep penetrating Class IIIB and Class IV Medical Laser Devices may only be sold to licensed medical practitioners (i.e. medical doctors, chiropractors, osteopaths, podiatrists and dentists). In some states an acupuncturist and/or nurse practitioner may be sold a laser.

The SHBAN Alcohol Free Persistent Hand Sanitizer may be sold to the general public as well as medical centers, hospitals, retail outlets, wholesalers and on the internet at www.shban.com.

The BioBody Balance Products can be sold to the general public, as well as medical centers, vitamin stores, retail outlets, wholesalers and on the internet at www.biobodybalance.net.

3. Status of any publicly announced new products or services;

The Company issues press releases on a quarterly basis or more frequently updates on the company its products and/or services. Products and/or services announced to the public within the past two years are fully operational as represented. The Company maintains new and old press releases for the past two years on its web site at www.biotechmedics.com.

4. Competitive business conditions, the issuer's competitive position in the industry, and methods of competition;

We will need to introduce new products and services to remain competitive. Our future success depends in part on our ability to develop and enhance our products and services. The healthcare and pain management services industry is characterized by technological change and the emergence of new industry standards and practices that could render our existing technology and systems obsolete. There are significant technical and financial risks in the development of new or enhanced products. These include the risk that we will be unable to effectively use new technologies or adapt our services to emerging industry standards, or develop, introduce and market enhanced or new products and services. In addition, the adoption of new Internet, networking or telecommunications technologies or other

technological changes could require us to incur substantial expense to modify or adapt our services or infrastructure.

We may make acquisitions, and we may be unable to successfully integrate those acquisitions with our business, impairing our financial performance.

If appropriate opportunities present themselves, we may acquire businesses, products or technologies that we believe are strategic. If we do succeed in acquiring a business, product or technology, we have limited experience in integrating an acquisition into our business. The process of integration may produce unforeseen operating difficulties and expenditures and may absorb significant attention of our management that would otherwise be available for the ongoing development of our business, which may harm our business, financial condition or results of operations.

Failure to comply with governmental requirements could adversely affect our business.

There are over 37 known worldwide laser manufacturers that produce flashlight size or small battery pack lasers that sell within a range of \$ 750 to \$39,995. Many low powered or “cold lasers” are utilized on animals by veterinarians and have been upgraded for human use.

The few desktop flashlight lasers designed for physicians range in price from \$2,500 to \$24,999. They operate at one-tenth to one-half the power of the high powered deep penetrating BioTech L3aser machines. Consequently, to accomplish what the BioTech L3aser does in 5 to 20 minutes over one-quarter of a human body would take a competitor’s laser over eight hours and numerous visits to the doctor’s office.

The SHBAN persistent antiseptic solution is protected by 4 US Letters of Patent owned by the Company. SHBAN is a very powerful persistent antibacterial antiseptic. It is superior because it is non-bleaching, odorless, colorless, non-flammable and non-toxic; therefore, when used as directed it is quick and safe to use around humans, animals and it does not harm the environment.

5. Sources and availability of raw materials and the names of principal suppliers;

Our sources are many as to raw materials and equipment. The Company is not dependent on any one major principal supplier.

6. Dependence on one or a few major customers;

We do not depend on one or a few major customers. Our ability to attract and retain customers and employees may be adversely affected to the extent our reputation is damaged. If we fail, or appear to fail, to deal with various issues that may give rise to reputation risk, we could harm our business prospects. These issues include, but are not limited to, appropriately dealing with potential conflicts of interest, legal and regulatory requirements, ethical issues, privacy, record-keeping, sales practices, and the proper identification of the legal, reputation, credit, liquidity, and market risks inherent in our business.

Failure to appropriately address these issues could also give rise to additional legal risk to us, which could, in turn, increase the size and number of claims and damages asserted against us or subject us to regulatory enforcement actions, fines, and penalties.

System failures and delays could harm our business.

We will receive and process sales/orders through a variety of electronic channels. Our execution services are dependent on the integrity of the systems supporting them. Our systems and operations and those of our third-party service providers are vulnerable to damage or interruption from human error, sabotage, encryption failures, break-ins, intentional acts of vandalism, earthquakes, terrorist attacks, floods, fires, power loss, telecommunications failures, computer viruses, computer denial of service attacks or other attempts to harm our systems and operations, and similar events.

Our disaster recovery planning cannot account for all eventualities. While we have invested significant amounts to upgrade the reliability and scalability of our systems, there can be no assurance that our systems will be sufficient to handle all events. System failures or delays may occur in the future and could cause, among other things, unanticipated disruptions in service to our customers, slower system response time resulting in transactions not being processed as quickly as our customers desire, decreased levels of customer service and customer satisfaction and harm to our reputation. If any of these events were to occur, we could suffer:

- a loss of customers or a reduction in the growth of our customer base;
- increased operating expenses;
- financial losses;
- litigation or other customer claims; and
- regulatory sanctions or additional regulatory burdens.

Our business also depends on the continued reliability of the Internet infrastructure. This includes maintenance of a reliable network backbone with the necessary speed, data capacity and security for providing reliable Internet services. Internet infrastructure may be unable to support the demands placed on it if the number of Internet users continues to increase, or if existing or future Internet users access the Internet more often or increase their bandwidth requirements. In addition, viruses, worms and similar programs may harm the performance of the Internet. The Internet has experienced a variety of outages and other delays as a result of damage to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage and our business could be materially adversely affected. Our networks and those of our third-party service providers may be vulnerable to security risks.

The secure transmission of confidential information over public networks is an element of our operations. Our networks and those of our third-party service providers may be vulnerable to unauthorized access, computer viruses and other security problems. Persons who circumvent security measures could wrongfully use our confidential information or our customers' confidential information, or cause interruptions or malfunctions in our operations. We, or our service providers may be required to expend significant additional resources to protect against the threat of security breaches or to alleviate problems caused by any breaches. We or our service providers may not be able to implement security measures that will protect against all security risks. Our inability to protect our intellectual property rights or our infringement of the intellectual property rights of others could adversely affect our

business. Our success and ability to compete in the securities industry depends in part upon our technology.

7. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration;

The four (4) U.S. Letters of Patent, owned by the Company, called the “SHBAN patents” require that a net royalty be paid to the original patent holders via FHJ Scientific for the life of the patents.

The Company has previously filed with the US Patent & Trademark Office for trademarks on BioTech Medics, BioTech L3asers, SHBAN. Renewals are due at this time or re-filings due to a change in Patent and Trademark legislation within the past two years.

The Company has no union labor contracts.

8. The need for any government approval of principal products or services. Discuss the status of any requested government approvals.

Fortunately, all current government approvals are complete. It took over ten years to receive the various government approvals of the lasers, and OTC products we either manufacture, or distribute or use.

Laws and our contractual terms may not be sufficient to protect our technology from use or theft by third parties. For instance, a third party might try to reverse engineer or otherwise obtain and use our technology without our permission and without our knowledge, allowing competitors to duplicate our products. We may have legal or contractual rights that we could assert against such illegal use, but lawsuits claiming infringement or misappropriation are complex and expensive, and the outcome would not be certain. We may choose not to enforce or protect our intellectual property rights, depending on our strategic evaluation and judgment regarding the best use of our intellectual property portfolio and the recourse available to us.

Patents of third parties may have an important bearing on our ability to offer certain of our products and services. Our major competitors as well as other companies and individuals may obtain and may have obtained patents related to the technologies for trading the types of products and providing the services we offer or plan to offer. We cannot assure you that we are or will be aware of all patents containing claims that may pose a risk of infringement by our products and services. In addition, some patent applications in the United States are confidential until a patent is issued and, therefore, we cannot evaluate the extent to which technology concerning our products and services may be covered or asserted to be covered by claims contained in pending patent applications. In general, if one or more of our products or services is found by a court to infringe patents held by others, we may be required to stop developing or marketing the products or services, to obtain licenses to develop and market the services from the holders of the patents or to redesign the products or services in such a way as to avoid infringing those patents. An adverse ruling arising out of any intellectual property dispute could also subject us to significant liability for damages.

We cannot assess the extent to which we may be required in the future to obtain licenses with respect to patents held by others, whether such licenses would be available or, if available, whether we would be able to obtain such licenses on commercially reasonable terms. If we are unable to obtain licenses with respect to patents held by others, and are unable to redesign our products or services to avoid infringement of any such patents, this could materially adversely affect our business, financial condition and operating results. Also, protection may not be available for our other intellectual property.

Item 10. Nature and Extent of Issuer’s Facilities:

The Company maintains its Nevada legal corporate offices at Corporate Services of Nevada, 507 North Division Street, Carson City, NV 89703 on an annual contract basis.

BioTech’s Texas medical affiliated clinic is located at 7920 Belt Line Road, Suite 120, Dallas, TX 75234. A month to month lease agreement in a shared 3,500 square foot medical office is in place.

We do not own any real estate property or properties for which the book value amounts to 10 percent or more of the total assets of the Company and its consolidated subsidiaries for the last fiscal year.

The Company is registered with the Texas Secretary of State as a “foreign entity” so that the Company may operate in Texas.

Item 11. Name of the Chief Executive Officer, Members of the Board of Directors, as well as Counsel, Accountant and Public Relations Consultant:

A. Officers, Directors and Advisors

1. Management

Our directors and officers are as follows:

Name

Title

Keith A. Houser

Chairman of the Board and Chief Executive Officer and Secretary

Charles R. Crane

President and Director

Keith A. Houser has been our Chairman of the Board and Chief Executive Officer since December 7, 2004. Previously, Mr. Houser founded from 2001 to 2004 and was president of HaloLaser BioTherapy, LLC (“Halo”), which became the former primary distributor for the NeuroLase Medical Laser Device and merged with BioTech Medics in December 2004. Mr. Houser has an extensive marketing background in radio and television broadcasting from

1966 through 2000. He has managed, owned and/or operated radio and television states from Phoenix, AZ to New York City.

As of the date we provided information in response to this item, the BioTech Medics Investment Unit Trust has proxy authority for Sixty-five Percent (65%) of the shares of BMCS common stock.

Charles R. Crane has been our President and Director since December 7, 2004. Over the past thirty years, Dr Crane has operated a private medical practice, specializing in Physical Medicine & Rehabilitation and Electromyography. In addition, he is currently a medical consultant for ReviewMed. He is not currently a member of any other public board of directors. As of the date we provided information in response to this item, he has in trust over 23 million shares of BMCS common stock for his benefit.

Because insiders control our activities, they may cause us to act in a manner that is most beneficial to them and not to outside shareholders, which could cause us not to take actions that outside investors might view favorably.

Our executive officers, directors, and holders of 5% or more of our outstanding Common Stock beneficially own approximately 80% of our outstanding Common Stock. As a result, they effectively control all matters requiring director and stockholder approval; including the election of directors and the approval of significant corporate transactions, such as mergers and related party transactions. These insiders also have the ability to delay or perhaps even block, by their ownership of our stock, an unsolicited tender offer. This concentration of ownership could have the effect of delaying, deterring or preventing a change in control of our company that you might view favorably.

Our management decisions are made by our CEO, Mr. Keith Houser; if we lose his services, our revenues may be reduced.

The success of our business is dependent upon the expertise of our CEO Keith Houser. Because he is essential to our operations, you must rely on their management decisions. He will continue to control our business affairs after this filing. We have no written employment agreement with him. We have not obtained any key man life insurance relating to him. If we lose his services, we may not be able to hire and retain another CEO with comparable experience. As a result, the loss of Keith Houser's services could reduce our revenues.

2. General Partners;

None.

3. Investment Banker;

None.

4. Promoters;

PMR Associates of California

5. Control Persons;

Please see the above disclosure for Keith A. Houser, Charles R. Crane

6. Legal Counsel;

The Company Texas corporate legal counsel is:
David Morris, Esq.
The Morris Law Firm
Dallas, Texas

Nevada legal counsel is
R. Chris Reade, Esq.
Christopher Reade & Associates Law Firm
Las Vegas, Nevada

Litigation Attorneys,
Kirk Smith, Esq.
Shepherd, Smith Edwards & Kantas, L.L.P..
1010 Lamar, Suite 900.
Houston, TX 77002

7. Accountant or Auditor;

The Company does not currently have an auditor; we have had two prior CPA firms in the past. We are actively interviewing for a new firm at this time.

8. Public Relations Consultant.

No one at this time.

B. Legal/Disciplinary History

To the best of our knowledge, none of the foregoing persons has, during the last ten years, been the subject of the following except as follows:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated;

No.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

No.

C. Beneficial Owners The following table sets forth, as of December 31, 2011, certain information with respect to the Company's equity securities owned on record or beneficially by (i) each Officer and Director of the Company; (ii) each person who owns beneficially more than five percent (5%) of each class of the Company's outstanding equity securities; and (iii) all Directors and Executive Officers as a group.

Common Stock

Title of Name and Address Amount and Nature of Percent Class of Beneficial Owner

(1) Beneficial Ownership of Class (2) Common

(1) BioTech Medics Investment Unit Trust, FBO, The Texas H Trust

(2) 80,000,000 Common Shares equal to 50.89%

(1) BioTech Medics Investment Unit Trust, FBO Charles R. Crane, Trustee

(2) 23,000,000 Common Shares equal to 14.63%

Common Executive Officers and Directors as a Group

(2 Persons)

(1) Rufus Henscheid

(2) 12,008,010 Common Shares equal to 7.63%

The BioTech Medics Investment Unit Trust, sold within 120 days of the date of this filing 5,000,000 shares privately to an accredited investor for the sum of Two Cents (\$.02) per share. This was at the fair market value at the time of the sale. The shares were originally 144 stock issued over twenty-four months prior to the sale.

(1) Unless otherwise noted, the address of each beneficial owner is in c/o The Company.

(2) Based on 157 million shares outstanding as of December 31, 2011, 15 million shares of common stock are subject to options or warrants currently exercisable, or exercisable within 60 days, are deemed outstanding for purposes of computing the percentage of the person holding such options or warrants, but are not deemed outstanding for purposes of computing the percentage of any other person.

D. Disclosure of Certain Relationships

Approximately 65.52% of our outstanding shares of common stock are held by BioTech Medics Investment Unit Trust, of which Keith A. Houser, Chairman of the Board and Chief Executive Officer, Charles R. Crane, our President and Director, are beneficiaries.

There are no family relationships regarding the directors or officers of the corporation.

Item 12.

Issuer's Most Recent Balance Sheet and Profit and Loss and Retained Earnings Statements:

Our unaudited financial statements as of the quarter plus ended December 31, 2011, are enclosed herewith. No CPA has completed review of these statements.

Item 13.

Similar Financial Information for Such Part of the Two Preceding Fiscal Years as the Issuer or its Predecessor Has Been in Existence:

Our unaudited financial statements as of the end of the last two fiscal years ended December 31, 2010, and 2011, are enclosed herewith.

Item 14.

Whether Quotation is Being Submitted or Published Directly on Behalf of Issuer, or any Director, Officer, or any Person, the Beneficial Owner of More Than Ten Percent (10%) of the Outstanding Shares of the Issuer's Equity Securities, and, if so, the Name of Such Person, and Basis for any Exemption under the Federal Securities Laws for any Sale of Such Securities on Behalf of Such Person:

To the best of management's knowledge, no quotations are being submitted by any broker or dealer directly on behalf of the Issuer or any director, officer, or ten percent (10%) shareholders.

However, during the prior six (6) years, the Company has had to file numerous FINCEN Suspicious Activity Reports (SARS) with the FBI, SEC and other regulatory agencies in reporting the illegal manipulation of the Company stock which subsequently became a criminal matter overseen by the US Dept of Justice, US Attorney General, Las Vegas, NV.

The Company and its officer Keith Houser has made direct contact with various "Compliance Officers" of various formerly NASD now FINRA registered broker dealers (i.e. eTrade, Knight Securities, Hudson, Merrill Lynch, Hill & Thompson, Murphy & Durieu, TD Ameritrade, Citigroup, NevWest Securities, Vertical Group and Ameritrade) to advise them of the illegal manipulation and SARS violations relating to the Company stock by one or more persons prohibited by one or more U.S. District Federal Judicial Orders. Specifically, one such Order was issued by the Honorable Elizabeth A. Kovachevich, US Dist Judge for the Middle District of Florida, Tampa Division, Case No. 8:02-cv-00822-EAK in December, of 2003 and subsequently finalized in July 15, 2008 against Jeffrey G. Turino, et al. The

second Order was issued by the Honorable Larry R. Hicks, US Dist Judge for the US District Court of Nevada against John Edwards, et al, Case No. 2:08-cv-00437-LRH-RJJ. Mr. Houser has sent “Cease & Desist” notices to various broker dealers with copies of the U.S. District Federal Judicial Orders. The results thereof, on a very limited basis, has facilitated by some broker dealers the removal of a manipulated “bid” and/or “ask” of the stock.

Copies of the FINCEN SARS reports were filed immediately with the SEC/FBI and various other regulatory authorities to comply with full disclosure regulations. Mr. Houser’s actions would be exempt from violating any federal securities laws as follows:

Safe Harbor Federal law (31 U.S.C. 5318(g)(3)) provides complete protection from civil liability for all reports of suspicious transactions made to appropriate authorities, including supporting documentation, regardless of whether such reports are filed pursuant to this report’s instructions or are filed on a voluntary basis. Specifically, the law provides that an institution, and its directors, officers, employees, and agents, that make a disclosure of any possible violation of law or regulation, including in connection with the preparation of suspicious activity reports, “shall not be liable to any person under any law or regulation of the United States, any constitution, law, or regulation of any State or political subdivision of any State, or under any contract or other legally enforceable agreement (including any arbitration agreement), for such disclosure or for any failure to provide notice of such disclosure to the person who is the subject of such disclosure or any other person identified in the disclosure.”.

Mr. Houser just advised the broker dealers of the existence of the Orders, that they were to comply with the Orders and the subjects thereof for the protection of the existing legal shareholders of the Company. Sadly most broker dealers disregard the judicial Orders. NevWest Securities was one such dealer.

The Company as a part of our policy used to identify, monitor and control risks, the Company has posted or had posted on various bulletin boards from time to time rebuttals of scurrilous, unfounded, libelous posts disparaging the Company and/or its products, and/or officers, and/or directors and/or their family members and/or shareholders of the Company. Some of the postings have been forwarded to the SEC for full disclosure as some of the posters have been stalking and disparaging the Company for over seven (7) years. At all times the posts the Company did not solicit any person to invest in the Company or buy stock, but reposted in most cases prior public announcements previously published to clarify and/or to dispel the vicious false rumors, etc.

Since September, 2011 the State of Texas has passed “Spoofing” laws making it a crime for someone to post anonymously on the Internet false and disparaging remarks. The Company has noticed a slight decline in the disparaging posts since the passage of the Texas laws. There are no known incidents where these clarifying and or rebuttal posts influenced the price of the stock directly.

All information contained herein is subject to change, modification and/or revision without notice.

Our risk management policies and procedures may not be effective and may leave us exposed to unidentified or unexpected risks.

Our policies, procedures and practices used to identify, monitor and control a variety of risks may fail to be effective. As a result, we face the risk of losses, including losses resulting from firm errors, customer defaults, regulatory changes, fraud. Our risk management methods rely on a combination of technical and human controls and supervision that are subject to error and failure. Some of our methods of managing risk are based on internally developed controls and observed historical behavior, and also involve reliance on industry standard practices. These methods may not adequately prevent future losses, particularly as they relate to extreme market movements, which may be significantly greater than the historical measures indicate. These methods also may not adequately prevent losses due to technical errors if our testing and quality control practices are not effective in preventing technical software or hardware failures. We may suffer losses if our reputation is harmed.

This filing includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

In making an investment decision investors must rely on their own examination of the Company and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority; furthermore, these authorities have not passed upon the accuracy or adequacy of this information. Any representation to the contrary is a criminal offense.

In connection with implementing our business plans, we will experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including the following:

- our profitability;
- our ability to secure contracts;
- the effectiveness of our remediation processes; and
- the amount of our capital expenditures, including real estate development projects.

We cannot assure you that we will be able to obtain capital in the future to meet our needs. We have no sources of financing identified. If we cannot obtain additional funding, we may be required to:

- limit our ability to implement our business plan;
- limit our marketing efforts; and
- decrease or eliminate capital expenditures.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are acceptable to us. Any future capital investments could dilute or otherwise adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences, and privileges senior to our Common Stock. Any additional financing may not be available to us, or if available, may not be on terms favorable to us.

The information contained herein is presented as of the date of posted below. The posting of this information at any later date should not create any implication that there has been no change in the information set forth herein or in the financial condition or prospects of the Company. You should read all the information herein before making a decision whether to purchase our stock. You are encouraged to call the Company directly.

We lack a public market for shares of our common stock, which may make it difficult for investors to sell their shares.

There is no public market for shares of our common stock and an active public market may not develop or be sustained. Therefore, investors may not be able to find purchasers for their shares of our common stock. Further, the stock market has experienced extreme volatility that has particularly affected the market prices of stock of many companies, particularly start-up companies like ours.

An investment in the Company is speculative, involves a high degree of risk, and should be considered only by sophisticated accredited investors who can bear the economic risks of their investment for an indefinite period and who can afford to sustain a total loss of their investment.

Dated this 27th day of February 2012, Carson City, Nevada.

BIOTECH MEDICS, INC.


Authorized Electronic Signature

By: Keith A. Houser
The Company Chief Executive Officer